| Literature DB >> 12504661 |
M Marchand1, C J A Punt, S Aamdal, B Escudier, W H J Kruit, U Keilholz, L Håkansson, N van Baren, Y Humblet, P Mulders, M-F Avril, A M M Eggermont, C Scheibenbogen, J Uiters, J Wanders, M Delire, T Boon, G Stoter.
Abstract
Fifty-seven patients with MAGE-3-positive measurable metastatic cancer, most of them with melanoma, were vaccinated with escalating doses of a recombinant MAGE-3 protein combined with a fixed dose of the immunological adjuvant SBAS-2, which contained MPL and QS21. The immunisation schedule included 4 intramuscular (i.m.) injections at 3-week intervals. Patients whose tumour stabilised or regressed after 4 vaccinations received 2 additional vaccinations at 6-week intervals. The vaccine was generally well tolerated. Among the 33 melanoma patients who were evaluable for tumour response, we observed 2 partial responses, 2 mixed responses and 1 stabilisation. Time to progression in these 5 patients varied from 4 to 29 months. In addition, a partial response lasting 10 months was observed in 1 of the 3 metastatic bladder cancer patients included. None of the tumour responses described above involved visceral metastases. Immunological responses to the vaccine will be reported separately.Entities:
Mesh：
Substances：
Year: 2003 PMID： 12504661 DOI： 10.1016/s0959-8049(02)00479-3
Source DB: PubMed Journal: Eur J Cancer ISSN： 0959-8049 Impact factor: 9.162